Literature DB >> 32476940

A composite score to assess treatment response in pulmonary sarcoidosis: the Sarcoidosis Treatment Score (STS).

Robert P Baughman1, Michael Tillinger2, Yimin Qin2, Nadera Sweiss3, Elyse E Lower1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2019        PMID： 32476940      PMCID： PMC7247109          DOI： 10.36141/svdld.v36i1.7748

Source DB:  PubMed          Journal:  Sarcoidosis Vasc Diffuse Lung Dis        ISSN： 1124-0490            Impact factor:   0.670


× No keyword cloud information.
  10 in total

1.  British Thoracic Society Sarcoidosis study: effects of long term corticosteroid treatment.

Authors:  G J Gibson; R J Prescott; M F Muers; W G Middleton; D N Mitchell; C K Connolly; B D Harrison
Journal:  Thorax       Date:  1996-03       Impact factor: 9.139

2.  Steroid-sparing effects of pentoxifylline in pulmonary sarcoidosis.

Authors:  M K Park; H Babaali; L I Gilbert-McClain; M Stylianou; J Joo; J Moss; V C Manganiello
Journal:  Sarcoidosis Vasc Diffuse Lung Dis       Date:  2009-07       Impact factor: 0.670

Review 3.  Sarcoidosis.

Authors:  Dominique Valeyre; Antje Prasse; Hilario Nunes; Yurdagul Uzunhan; Pierre-Yves Brillet; Joachim Müller-Quernheim
Journal:  Lancet       Date:  2013-10-01       Impact factor: 79.321

4.  The development and validation of the King's Sarcoidosis Questionnaire for the assessment of health status.

Authors:  Amit Suresh Patel; Richard J Siegert; Daniel Creamer; Genevieve Larkin; Toby M Maher; Elisabetta A Renzoni; Athol U Wells; Irene J Higginson; Surinder S Birring
Journal:  Thorax       Date:  2012-10-12       Impact factor: 9.139

5.  The six-minute walk test in patients with pulmonary sarcoidosis.

Authors:  Esam H Alhamad
Journal:  Ann Thorac Med       Date:  2009-04       Impact factor: 2.219

6.  Serum angiotensin-converting enzyme activity in evaluating the clinical course of sarcoidosis.

Authors:  R A DeRemee; M S Rohrbach
Journal:  Ann Intern Med       Date:  1980-03       Impact factor: 25.391

7.  Infliximab for the therapy of chronic sarcoidosis, Baughman RP, Drent M, Kavuru M et al.: Infliximab therapy in patients with chronic sarcoidosis and pulmonary involvement. Am. J. Respir. Crit. Care Med. (2006) 174(7):795-802.

Authors:  Sabina A Antoniu
Journal:  Expert Opin Investig Drugs       Date:  2007-05       Impact factor: 6.206

Review 8.  Endpoints for clinical trials of sarcoidosis.

Authors:  R P Baughman; M Drent; D A Culver; J C Grutters; T Handa; M Humbert; M A Judson; E E Lower; J Mana; C A Pereira; A Prasse; R Sulica; D Valyere; V Vucinic; A U Wells
Journal:  Sarcoidosis Vasc Diffuse Lung Dis       Date:  2012-10       Impact factor: 0.670

9.  Measuring fatigue in sarcoidosis: the Fatigue Assessment Scale (FAS).

Authors:  Jolanda De Vries; Helen Michielsen; Guus L Van Heck; Marjolein Drent
Journal:  Br J Health Psychol       Date:  2004-09

10.  Repository corticotropin for Chronic Pulmonary Sarcoidosis.

Authors:  Robert P Baughman; Nadera Sweiss; Ruth Keijsers; Surinder S Birring; Ralph Shipley; Lesley Ann Saketkoo; Elyse E Lower
Journal:  Lung       Date:  2017-03-28       Impact factor: 2.584
  10 in total
  2 in total

1.  Understanding Predictors of Response to Repository Corticotropin Injection Treatment Among Patients With Advanced Symptomatic Sarcoidosis.

Authors:  Jas Bindra; Ishveen Chopra; Kyle Hayes; John Niewoehner; Mary P Panaccio; George J Wan
Journal:  J Health Econ Outcomes Res       Date:  2022-04-20

Review 2.  Repository Corticotropin Injection for the Treatment of Pulmonary Sarcoidosis: A Narrative Review.

Authors:  Mehdi Mirsaeidi; Robert P Baughman
Journal:  Pulm Ther       Date:  2022-02-03
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.